Astrazeneca ADR Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Astrazeneca ADR Stock
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Astrazeneca ADR stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Astrazeneca ADR in the next few years
Pros
?
M***** P*******
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Astrazeneca ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Astrazeneca ADR | - | - | - | - | - | - | - |
| GSK plc ADR | 2.330% | -3.153% | -2.715% | 18.785% | 2.871% | 34.375% | 7.500% |
| Bayer AG ADR | 0.600% | -11.828% | -14.136% | 33.333% | -6.818% | -35.938% | -38.346% |
| Roche Holding AG ADR | -0.530% | -6.641% | -1.850% | 18.922% | -3.550% | 12.045% | 17.304% |
News
Velan Capital Drops 140,000 Mineralys Therapeutics (MLYS) Shares Worth $4.1 Million
According to an SEC filing dated May 15, 2026, Velan Capital Investment Management LP sold 140,000 shares of Mineralys Therapeutics in the first quarter. The estimated value of the trade was $4.11
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
Key Points
- Interested in Inovio Pharmaceuticals, Inc.? Here are five stocks we like better.
- Shareholders approved all proposals at Inovio’s 2026 annual meeting, including the election of eight
Alnylam Pharmaceuticals Backs TTR Outlook as AMVUTTRA Access, Prescriber Growth Build
Alnylam Pharmaceuticals (NASDAQ:ALNY) Chief Financial Officer Jeff Poulton said the company remains confident in its TTR revenue guidance